[go: up one dir, main page]

HUP9800649A2 - Benzil-oxi-csoporttal helyettesített, kondenzált N-heterociklusos vegyületek, eljárás előállításukra és alkalmazásuk bradikinin receptorantagonistaként - Google Patents

Benzil-oxi-csoporttal helyettesített, kondenzált N-heterociklusos vegyületek, eljárás előállításukra és alkalmazásuk bradikinin receptorantagonistaként

Info

Publication number
HUP9800649A2
HUP9800649A2 HU9800649A HUP9800649A HUP9800649A2 HU P9800649 A2 HUP9800649 A2 HU P9800649A2 HU 9800649 A HU9800649 A HU 9800649A HU P9800649 A HUP9800649 A HU P9800649A HU P9800649 A2 HUP9800649 A2 HU P9800649A2
Authority
HU
Hungary
Prior art keywords
bradiquinin
condesed
benzyloxy
antagonists
receptor
Prior art date
Application number
HU9800649A
Other languages
English (en)
Inventor
Holger Heitsch
Bernward Schölkens
Adalbert Wagner
Klaus Wirth
Original Assignee
Hoechst Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag. filed Critical Hoechst Ag.
Publication of HU9800649D0 publication Critical patent/HU9800649D0/hu
Publication of HUP9800649A2 publication Critical patent/HUP9800649A2/hu
Publication of HUP9800649A3 publication Critical patent/HUP9800649A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya az új, (I) általánős képletű vegyületek, ahől Djelentése (II) vagy (III) általánős képletű gyök, X1 jelentése N vagyC-R6, X2 jelentése N vagy C-R7, X3 jelentése N vagy C-R8, B jelentése(VIII) általánős képletű csőpőrt, R1, R2 jelentése, amelyek lehetnekazőnősak vagy különbözők: 1. hidrőgénatőm, 2. halőgénatőm, 3. (C1-C3)-alkilcsőpőrt. A találmány tárgya tővábbá ezeknek a vegyületeknek azelőállítása, valamint alkalmazásűk gyógyszerként májzsűgőr ésAlzheimer-kór kezelésére és megelőzésére. ŕ
HU9800649A 1997-03-27 1998-03-25 Condesed n-heterocyclic compounds substituted with benzyloxy-group, process for producing them, and their use as bradiquinin-receptor-antagonists HUP9800649A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712960A DE19712960A1 (de) 1997-03-27 1997-03-27 Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten

Publications (3)

Publication Number Publication Date
HU9800649D0 HU9800649D0 (en) 1998-05-28
HUP9800649A2 true HUP9800649A2 (hu) 1998-12-28
HUP9800649A3 HUP9800649A3 (en) 1999-01-28

Family

ID=7824838

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800649A HUP9800649A3 (en) 1997-03-27 1998-03-25 Condesed n-heterocyclic compounds substituted with benzyloxy-group, process for producing them, and their use as bradiquinin-receptor-antagonists

Country Status (16)

Country Link
US (1) US6211196B1 (hu)
EP (1) EP0867432B1 (hu)
JP (1) JPH10279563A (hu)
KR (1) KR19980080757A (hu)
CN (1) CN1194978A (hu)
AT (1) ATE268759T1 (hu)
AU (1) AU5965298A (hu)
BR (1) BR9801132A (hu)
CA (1) CA2232499A1 (hu)
CZ (1) CZ91498A3 (hu)
DE (2) DE19712960A1 (hu)
ES (1) ES2223090T3 (hu)
HU (1) HUP9800649A3 (hu)
NO (1) NO981383L (hu)
PL (1) PL325597A1 (hu)
TR (1) TR199800543A2 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
US6492517B1 (en) * 2001-07-19 2002-12-10 Air Products And Chemicals, Inc. Method for preparing halomethyl heterocyclic compounds
EP1495017A2 (en) * 2002-04-10 2005-01-12 Ortho-McNeil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US7056937B2 (en) * 2002-05-03 2006-06-06 Elan Pharmaceuticals, Inc. Sulfonylquinoxalone derivatives as bradykinin antagonists
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
BRPI0607404A2 (pt) 2005-03-01 2009-09-01 Wyeth Corp compostos de cinolina e seu uso como moduladores de receptor de x hepático
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
ES2749186T3 (es) 2014-05-07 2020-03-19 Evotec Int Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
HUE058217T2 (hu) 2017-11-24 2022-07-28 Pharvaris Netherlands B V Új bradikinin B2 receptor antagonisták
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
DK4203919T3 (da) 2021-08-05 2024-04-29 Pharvaris Gmbh Lipidbaseret sammensætning til oral administration af bradykinin-b2-receptorantagonister
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
IL315699A (en) 2022-03-25 2024-11-01 Pharvaris Gmbh A solid composition comprising dissolved bradykinin B2 receptor antagonists
EP4499100A1 (en) 2022-03-25 2025-02-05 Pharvaris GmbH Therapeutic uses of bradykinin b2-receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202336A (en) * 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
JP3697486B2 (ja) * 1994-10-27 2005-09-21 アステラス製薬株式会社 ブラジキニン拮抗剤としての、ピリドピリミドン類、キノリン類および縮合ｎ−複素環類
FR2735128B1 (fr) * 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2737892B1 (fr) * 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19610784A1 (de) * 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0808627A2 (de) 1996-05-22 1997-11-26 Hoechst Aktiengesellschaft Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
JP4189045B2 (ja) * 1996-10-14 2008-12-03 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマー病の治療および予防用の医薬を製造するための非ペプチドのブラジキニンアンタゴニストの使用

Also Published As

Publication number Publication date
MX9802372A (es) 1998-09-30
DE19712960A1 (de) 1998-10-01
NO981383D0 (no) 1998-03-26
BR9801132A (pt) 2000-03-21
TR199800543A2 (xx) 1998-10-21
CZ91498A3 (cs) 1998-10-14
CA2232499A1 (en) 1998-09-27
AU5965298A (en) 1998-10-01
PL325597A1 (en) 1998-09-28
NO981383L (no) 1998-09-28
ES2223090T3 (es) 2005-02-16
HUP9800649A3 (en) 1999-01-28
ATE268759T1 (de) 2004-06-15
DE59811526D1 (de) 2004-07-15
KR19980080757A (ko) 1998-11-25
HU9800649D0 (en) 1998-05-28
CN1194978A (zh) 1998-10-07
EP0867432B1 (de) 2004-06-09
EP0867432A3 (de) 1998-10-14
US6211196B1 (en) 2001-04-03
JPH10279563A (ja) 1998-10-20
EP0867432A2 (de) 1998-09-30

Similar Documents

Publication Publication Date Title
HUP9800649A2 (hu) Benzil-oxi-csoporttal helyettesített, kondenzált N-heterociklusos vegyületek, eljárás előállításukra és alkalmazásuk bradikinin receptorantagonistaként
FI913478A0 (fi) Diazinderivat.
HUP0004419A2 (hu) Aril-oxi-alkil-dialkil-amin-származékok és előállításuk
BG105177A (en) Novel substituted pyrazole derivatives
CY1106297T1 (el) Παραγωγα πυραζολης χρησιμα ως αναστολεις κινασης πρωτεϊνης
NO20025955L (no) 1,2-dihydropyridinforbindelser, fremgangsmåte for fremstilling av de sammeog anvendelse derav
NO910712L (no) Fremgangsmaate ved fremstilling av oksetanoner.
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
SE0102299D0 (sv) Compounds
SE0102300D0 (sv) Compounds
ES2163638T3 (es) Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas.
HUP9700884A2 (hu) Tienil-etilamino-halogénfenil-acetamid intermedierek és eljárás előállításukra
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE12503T1 (de) 1-beta-d-arabinofuranosyl-(e)-5-(2halogensubstituiertes vinyl) uracil-5-phosphate; ihre herstellung und verwendung.
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE237585T1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
ATE196899T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
HU9300533D0 (en) Tropolone derivatives, method for producing them medical preparatives for preventing and treating ischemic diseases containing said compounds and method for preparing them
ES2194102T3 (es) Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
DE59910677D1 (de) Verfahren sowie neue zwischenprodukte zur herstellung von isoxazolin-3-yl-acylbenzolen
TW200619212A (en) Morpholine derivatives
CY1105550T1 (el) Μεμνο-πεπτιδια, μια διαδικασια για την παρασκευη και τη χρηση τους
MXPA05004845A (es) N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.